Work

Intradermal administration of novel particulate Chlamydia trachomatis vaccine candidates drives protective immune responses

Year: 2024

Type: article

Abstract: Chlamydia trachomatis causes the most prevalent bacterial sexually transmitted infection worldwide. Its complex lifecycle and the lack of appropriate antigen delivery vehicles make it difficult to develop an effective C. trachomatis vaccine. Recently, bacterial protein bodies (PBs) have emerged as promising bioparticles for vaccine antigen delivery. By developing a PB-tag for translational fusion, we were able to induce the aggregation of recombinant antigens expressed in Escherichia coli into PBs. Here, we investigated the immunogenicity and efficacy of PBs containing either the C. trachomatis MOMP-derived CTH522-SP or HtrA antigen in mice. Intradermal administration of c-di-AMP-adjuvanted PB-CTH522-SP and PB-HtrA vaccines, produced in an LPS-detoxified E. coli strain, induced antigen-specific cellular immunity, as measured by significant release of IFN-γ and IL17a in draining cervical lymph node and splenic cell cultures. Moreover, significant induction of HtrA-specific IFN-γ expressing CD4 + and CD8 + T cells was detected in the spleens. While immunization with the two PB vaccines led to prominent levels of specific antibodies in both serum and vaginal compartments, only antiserum against PB-CTH522-SP exhibited C. trachomatis -specific neutralization activity. Importantly, intradermal immunization with PB-CTH522-SP significantly reduced bacterial counts following C. trachomatis genital challenge. These data highlight the potential of the PB-based platform for the development of C. trachomatis vaccines. • Bacterial protein bodies (PBs) are promising for intradermal vaccine delivery. • Chlamydia PB vaccine candidates elicit strong cellular and humoral responses. • PB-based CTH522 vaccine induces high levels of neutralizing antibodies. • PB-CTH522 vaccination reduces C. trachomatis load after genital challenge. • PBs show potential for intradermal Chlamydia vaccine development.

Source: Biomedicine & Pharmacotherapy

DOI: 10.1016/j.biopha.2024.117563